首页 > 最新文献

Investigative and Clinical Urology最新文献

英文 中文
Extraperitoneal single-port robot-assisted radical prostatectomy: Short-term outcomes and technique description. 腹膜外单孔机器人辅助前列腺癌根治术:短期疗效和技术描述。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 DOI: 10.4111/icu.20230427
Hyeok Jae Kwon, San Kang, Seung Ah Rhew, Chang Eil Yoon, Dongho Shin, Seokhwan Bang, Hyong Woo Moon, Woong Jin Bae, Hyuk Jin Cho, U-Syn Ha, Ji Youl Lee, Sae Woong Kim, Sung-Hoo Hong

Purpose: We evaluated the feasibility, safety, and learning curve of extraperitoneal single-port robot-assisted radical prostatectomy (SP-RARP) and introduced innovative surgical techniques to maintain the instrument positions during the procedures.

Materials and methods: A cohort of 100 patients underwent extraperitoneal SP-RARP at our institution from December 2021 to April 2023. The procedures were performed by an experienced urology surgeon utilizing two surgical techniques for dissecting the posterior aspect of the prostate-"changing instrument roles" and "using camera inversion"-to prevent positional shifts between the camera and instruments.

Results: The mean operation time for SP-RARP was 93.58 minutes, and the mean console time was 65.16 minutes. The mean estimated blood loss during the procedures was 109.30 mL. No cases necessitated conversion to multi-port robot, laparoscopy, or open surgery, and there were no major complications during the hospital stay or in the short-term follow-up. Early outcomes of post-radical prostatectomy indicated a biochemical recurrence rate of 4.0% over a mean follow-up duration of 6.40 months, with continence and potency recovery rates of 92.3% and 55.8%, respectively. Analysis of the learning curve showed no significant differences in operation time, console time, and positive surgical margin rates between the initial and latter 50 cases.

Conclusions: Extraperitoneal SP-RARP is a feasible and safe option for the treatment of localized prostate cancer in skilled hands. Continued accrual of cases is essential for future comparisons of SP-RARP with multiport approaches.

目的:我们评估了腹膜外单孔机器人辅助前列腺癌根治术(SP-RARP)的可行性、安全性和学习曲线,并引入了创新手术技术,以在手术过程中保持器械位置:2021年12月至2023年4月期间,100名患者在我院接受了腹膜外SP-RARP手术。手术由一名经验丰富的泌尿外科外科医生进行,采用两种手术技术解剖前列腺后方--"改变器械角色 "和 "使用摄像头反转"--以防止摄像头和器械之间的位置偏移:SP-RARP的平均手术时间为93.58分钟,控制台的平均手术时间为65.16分钟。手术过程中的平均失血量为 109.30 毫升。没有病例需要转为多孔机器人、腹腔镜或开放手术,住院期间和短期随访中也没有出现重大并发症。根治性前列腺切除术后的早期结果显示,在平均6.40个月的随访期间,生化复发率为4.0%,尿失禁率和排尿能力恢复率分别为92.3%和55.8%。学习曲线分析显示,最初的 50 例与后 50 例在手术时间、控制台时间和手术切缘阳性率方面无明显差异:结论:腹膜外 SP-RARP 是治疗局部前列腺癌的一种可行且安全的方法。继续积累病例对于今后比较 SP-RARP 与多孔方法至关重要。
{"title":"Extraperitoneal single-port robot-assisted radical prostatectomy: Short-term outcomes and technique description.","authors":"Hyeok Jae Kwon, San Kang, Seung Ah Rhew, Chang Eil Yoon, Dongho Shin, Seokhwan Bang, Hyong Woo Moon, Woong Jin Bae, Hyuk Jin Cho, U-Syn Ha, Ji Youl Lee, Sae Woong Kim, Sung-Hoo Hong","doi":"10.4111/icu.20230427","DOIUrl":"10.4111/icu.20230427","url":null,"abstract":"<p><strong>Purpose: </strong>We evaluated the feasibility, safety, and learning curve of extraperitoneal single-port robot-assisted radical prostatectomy (SP-RARP) and introduced innovative surgical techniques to maintain the instrument positions during the procedures.</p><p><strong>Materials and methods: </strong>A cohort of 100 patients underwent extraperitoneal SP-RARP at our institution from December 2021 to April 2023. The procedures were performed by an experienced urology surgeon utilizing two surgical techniques for dissecting the posterior aspect of the prostate-\"changing instrument roles\" and \"using camera inversion\"-to prevent positional shifts between the camera and instruments.</p><p><strong>Results: </strong>The mean operation time for SP-RARP was 93.58 minutes, and the mean console time was 65.16 minutes. The mean estimated blood loss during the procedures was 109.30 mL. No cases necessitated conversion to multi-port robot, laparoscopy, or open surgery, and there were no major complications during the hospital stay or in the short-term follow-up. Early outcomes of post-radical prostatectomy indicated a biochemical recurrence rate of 4.0% over a mean follow-up duration of 6.40 months, with continence and potency recovery rates of 92.3% and 55.8%, respectively. Analysis of the learning curve showed no significant differences in operation time, console time, and positive surgical margin rates between the initial and latter 50 cases.</p><p><strong>Conclusions: </strong>Extraperitoneal SP-RARP is a feasible and safe option for the treatment of localized prostate cancer in skilled hands. Continued accrual of cases is essential for future comparisons of SP-RARP with multiport approaches.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea. 韩国最近批准使用膀胱内吉西他滨治疗非肌层浸润性膀胱癌后的短期疗效。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 DOI: 10.4111/icu.20240047
Gang Kyu Kim, Young Heun Jo, Jongsoo Lee, Hyun Ho Han, Won Sik Ham, Won Sik Jang, Ji Eun Heo

Purpose: In high-risk non-muscle-invasive bladder cancer (NMIBC), intravesical Bacillus Calmette-Guérin (BCG) is the standard adjuvant therapy post-transurethral resection of bladder tumor (TURBT). Intravesical gemcitabine, used as an alternative or second-line therapy amid BCG shortages, lacks outcome studies in the Korean population.

Materials and methods: Patients who received weekly intravesical gemcitabine for 6 weeks after TURBT from 2019 to 2022 were retrospectively investigated. Based on the American Urological Association risk classification, patients with high- or very high-risk NMIBC who refused cystectomy were included. Maintenance treatment was performed depending on their risk. Recurrence was defined as histologic confirmation on subsequent cystoscopic biopsies or TURBT. Disease free survival (DFS) was evaluated by the Kaplan-Meier method.

Results: The study included 60 patients, comprising 45 high-risk (group 1) patients with a median age of 76 years and 15 very high-risk (group 2) patients with a median age of 68 years. Among them, 28 patients had previously received intravesical BCG. Over a median follow-up of 22 months, recurrence occurred in 31 patients in group 1 and 11 in group 2. The DFS rates of the high-risk group and the very high-risk group were 57.8% versus 40% at 1 year, 20.7% versus 21.3% at 2 years and 20.7% versus 21.3% at 3 years, respectively (p=0.831). Tis stage (p=0.042) and prostatic urethra invasion (p=0.028) were significant predictors of DFS. Cancer-specific mortality rates were 2.2% in group 1 and 6.7% in group 2 (p=0.441).

Conclusions: Similar DFS outcome between high-risk and very high-risk patients were observed based on short-term results in Korea. This finding is crucial for clinical practice; however, studies analyzing more patients and long-term outcomes are needed.

目的:对于高风险非肌层浸润性膀胱癌(NMIBC),膀胱内注射卡介苗(BCG)是经尿道膀胱肿瘤切除术(TURBT)后的标准辅助疗法。在卡介苗短缺的情况下,膀胱内注射吉西他滨可作为替代疗法或二线疗法,但在韩国人群中缺乏疗效研究:回顾性调查了2019年至2022年期间TURBT术后每周接受vesical吉西他滨治疗6周的患者。根据美国泌尿协会的风险分类,纳入了拒绝膀胱切除术的高风险或极高风险 NMIBC 患者。根据他们的风险进行维持治疗。复发的定义是在随后的膀胱镜活检或TURBT中得到组织学确认。无病生存期(DFS)采用 Kaplan-Meier 法进行评估:研究共纳入了 60 名患者,其中包括 45 名高风险(第 1 组)患者,中位年龄为 76 岁;15 名极高风险(第 2 组)患者,中位年龄为 68 岁。其中,28 名患者曾接受过卡介苗静脉注射。高危组和极高危组的 DFS 率分别为:1 年时 57.8% 对 40%,2 年时 20.7% 对 21.3%,3 年时 20.7% 对 21.3%(P=0.831)。Tis分期(p=0.042)和前列腺尿道侵犯(p=0.028)是DFS的重要预测因素。癌症特异性死亡率第一组为2.2%,第二组为6.7%(P=0.441):结论:根据韩国的短期结果,高危和极高危患者的 DFS 结果相似。这一发现对临床实践至关重要,但还需要对更多患者和长期结果进行分析研究。
{"title":"Short-term outcomes of intravesical gemcitabine for non-muscle-invasive bladder cancer after recent approval for use in Korea.","authors":"Gang Kyu Kim, Young Heun Jo, Jongsoo Lee, Hyun Ho Han, Won Sik Ham, Won Sik Jang, Ji Eun Heo","doi":"10.4111/icu.20240047","DOIUrl":"10.4111/icu.20240047","url":null,"abstract":"<p><strong>Purpose: </strong>In high-risk non-muscle-invasive bladder cancer (NMIBC), intravesical Bacillus Calmette-Guérin (BCG) is the standard adjuvant therapy post-transurethral resection of bladder tumor (TURBT). Intravesical gemcitabine, used as an alternative or second-line therapy amid BCG shortages, lacks outcome studies in the Korean population.</p><p><strong>Materials and methods: </strong>Patients who received weekly intravesical gemcitabine for 6 weeks after TURBT from 2019 to 2022 were retrospectively investigated. Based on the American Urological Association risk classification, patients with high- or very high-risk NMIBC who refused cystectomy were included. Maintenance treatment was performed depending on their risk. Recurrence was defined as histologic confirmation on subsequent cystoscopic biopsies or TURBT. Disease free survival (DFS) was evaluated by the Kaplan-Meier method.</p><p><strong>Results: </strong>The study included 60 patients, comprising 45 high-risk (group 1) patients with a median age of 76 years and 15 very high-risk (group 2) patients with a median age of 68 years. Among them, 28 patients had previously received intravesical BCG. Over a median follow-up of 22 months, recurrence occurred in 31 patients in group 1 and 11 in group 2. The DFS rates of the high-risk group and the very high-risk group were 57.8% versus 40% at 1 year, 20.7% versus 21.3% at 2 years and 20.7% versus 21.3% at 3 years, respectively (p=0.831). Tis stage (p=0.042) and prostatic urethra invasion (p=0.028) were significant predictors of DFS. Cancer-specific mortality rates were 2.2% in group 1 and 6.7% in group 2 (p=0.441).</p><p><strong>Conclusions: </strong>Similar DFS outcome between high-risk and very high-risk patients were observed based on short-term results in Korea. This finding is crucial for clinical practice; however, studies analyzing more patients and long-term outcomes are needed.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Occurrence of liver abscess in patients with acute prostatitis. 急性前列腺炎患者出现肝脓肿。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 DOI: 10.4111/icu.20240152
Jeonghyouk Choi, Dong-Gi Lee

Purpose: Liver abscesses concomitant with acute prostatitis are rare and potentially fatal. We analyzed the occurrence of this condition and clinical characteristics of the affected patients.

Materials and methods: The medical records of 474 patients diagnosed with acute prostatitis between June 2006 and July 2022 were retrospectively reviewed. Patients in whom pathogens were not detected in serum or urine cultures were excluded. A total of 271 patients were included in the analysis. Patient characteristics and laboratory test results were compared between patients with acute prostatitis with and without liver abscesses.

Results: Fifteen patients (5.5%) were identified with simultaneous liver abscesses and acute prostatitis. The liver abscess group was younger than the non-liver abscess group in terms of mean age. In the univariate analysis, a high proportion of patients had diabetes mellitus, whereas a low proportion had hypertension. None of the underlying diseases, including benign prostatic hyperplasia, malignancy, or alcoholism, demonstrated a significant association with liver abscess in multivariate analysis; however, an association was observed in liver function test results. All patients with liver abscesses tested positive for Klebsiella pneumoniae.

Conclusions: When K. pneumoniae is identified in patients with acute prostatitis and abnormal liver function tests, considering the possibility of metastatic infection in other organs, including the liver, and performing an active evaluation is essential.

目的:急性前列腺炎并发肝脓肿十分罕见,且可能致命。我们分析了这种情况的发生率和患者的临床特征:回顾性审查了 2006 年 6 月至 2022 年 7 月期间确诊为急性前列腺炎的 474 例患者的病历。排除了血清或尿液培养未检测到病原体的患者。共有 271 名患者被纳入分析。比较了有肝脓肿和无肝脓肿的急性前列腺炎患者的特征和实验室检查结果:结果:15 名患者(5.5%)同时患有肝脓肿和急性前列腺炎。就平均年龄而言,肝脓肿组比非肝脓肿组年轻。在单变量分析中,患有糖尿病的患者比例较高,而患有高血压的患者比例较低。在多变量分析中,良性前列腺增生、恶性肿瘤或酗酒等基础疾病均与肝脓肿无明显关联;但肝功能检测结果显示两者之间存在关联。所有肝脓肿患者的肺炎克雷伯菌检测结果均呈阳性:结论:当在急性前列腺炎和肝功能检测异常的患者中发现肺炎克雷伯菌时,考虑到其他器官(包括肝脏)转移感染的可能性并进行积极的评估是至关重要的。
{"title":"Occurrence of liver abscess in patients with acute prostatitis.","authors":"Jeonghyouk Choi, Dong-Gi Lee","doi":"10.4111/icu.20240152","DOIUrl":"10.4111/icu.20240152","url":null,"abstract":"<p><strong>Purpose: </strong>Liver abscesses concomitant with acute prostatitis are rare and potentially fatal. We analyzed the occurrence of this condition and clinical characteristics of the affected patients.</p><p><strong>Materials and methods: </strong>The medical records of 474 patients diagnosed with acute prostatitis between June 2006 and July 2022 were retrospectively reviewed. Patients in whom pathogens were not detected in serum or urine cultures were excluded. A total of 271 patients were included in the analysis. Patient characteristics and laboratory test results were compared between patients with acute prostatitis with and without liver abscesses.</p><p><strong>Results: </strong>Fifteen patients (5.5%) were identified with simultaneous liver abscesses and acute prostatitis. The liver abscess group was younger than the non-liver abscess group in terms of mean age. In the univariate analysis, a high proportion of patients had diabetes mellitus, whereas a low proportion had hypertension. None of the underlying diseases, including benign prostatic hyperplasia, malignancy, or alcoholism, demonstrated a significant association with liver abscess in multivariate analysis; however, an association was observed in liver function test results. All patients with liver abscesses tested positive for <i>Klebsiella pneumoniae</i>.</p><p><strong>Conclusions: </strong>When <i>K. pneumoniae</i> is identified in patients with acute prostatitis and abnormal liver function tests, considering the possibility of metastatic infection in other organs, including the liver, and performing an active evaluation is essential.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of prostatic urethral angle and intravesical prostatic protrusion on surgical capsule calculi formation in the prostate: A retrospective study. 前列腺尿道角度和膀胱内前列腺突出对前列腺手术囊结石形成的作用:一项回顾性研究。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-09-01 DOI: 10.4111/icu.20240171
Jonathan Yj Chen, Han-Yu Tsai, Chen-Pang Hou, Shu-Han Tsao, Yu-Ting Chen, Horng-Heng Juang, Yu-Hsiang Lin

Purpose: To investigate the relationship between prostatic urethral angle (PUA) and the development of surgical capsule calculi (SCC) within the prostate, and to examine the presence and impact of intravesical prostatic protrusion (IPP).

Materials and methods: A retrospective analysis was conducted on 90 patients who underwent radical prostatectomy, with preoperative assessments using both transrectal ultrasound of the prostate (TRUS) and magnetic resonance imaging. Patients were divided into groups with and without SCC and further categorized into type 1 and type 2 stones based on the location and severity of the calculi. Statistical analysis included chi-square and independent sample t-tests, with p<0.05 considered significant.

Results: Of the patients, 82.2% were diagnosed with SCC. No significant difference in PUA was found between patients with and without SCC. However, a notable disparity in IPP presence was observed, suggesting an inverse correlation with SCC development. Additionally, no significant differences were identified when comparing the two types of SCC based on PUA and IPP measurements.

Conclusions: The presence of IPP exhibited an inverse relationship with SCC, suggesting diminished urine flow pressure over the prostatic urethra may reduce the likelihood of SCC formation. However, no direct association between PUA and the presence or severity of SCC was identified. These findings highlight the complexity of factors contributing to prostatic calculi development and the potential role of IPP in this context.

目的:研究前列腺尿道角(PUA)与前列腺内手术囊结石(SCC)发生之间的关系,并探讨膀胱内前列腺突出(IPP)的存在及其影响:对90名接受根治性前列腺切除术的患者进行了回顾性分析,术前使用经直肠前列腺超声(TRUS)和磁共振成像进行评估。患者被分为有 SCC 和无 SCC 两组,并根据结石的位置和严重程度进一步分为 1 型和 2 型结石。统计分析包括卡方检验和独立样本 t 检验,以及 p 结果:82.2%的患者被确诊为 SCC。患有和未患有 SCC 的患者在 PUA 方面没有明显差异。然而,IPP的存在却存在明显差异,这表明IPP与SCC的发展呈反向关系。此外,根据 PUA 和 IPP 测量结果对两种类型的 SCC 进行比较也未发现明显差异:结论:IPP的存在与SCC呈反比关系,表明前列腺尿道上的尿流压力降低可能会降低SCC形成的可能性。然而,PUA 与 SCC 的存在或严重程度之间并无直接关联。这些发现凸显了导致前列腺结石形成的因素的复杂性以及 IPP 在这方面的潜在作用。
{"title":"The role of prostatic urethral angle and intravesical prostatic protrusion on surgical capsule calculi formation in the prostate: A retrospective study.","authors":"Jonathan Yj Chen, Han-Yu Tsai, Chen-Pang Hou, Shu-Han Tsao, Yu-Ting Chen, Horng-Heng Juang, Yu-Hsiang Lin","doi":"10.4111/icu.20240171","DOIUrl":"10.4111/icu.20240171","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the relationship between prostatic urethral angle (PUA) and the development of surgical capsule calculi (SCC) within the prostate, and to examine the presence and impact of intravesical prostatic protrusion (IPP).</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted on 90 patients who underwent radical prostatectomy, with preoperative assessments using both transrectal ultrasound of the prostate (TRUS) and magnetic resonance imaging. Patients were divided into groups with and without SCC and further categorized into type 1 and type 2 stones based on the location and severity of the calculi. Statistical analysis included chi-square and independent sample t-tests, with p<0.05 considered significant.</p><p><strong>Results: </strong>Of the patients, 82.2% were diagnosed with SCC. No significant difference in PUA was found between patients with and without SCC. However, a notable disparity in IPP presence was observed, suggesting an inverse correlation with SCC development. Additionally, no significant differences were identified when comparing the two types of SCC based on PUA and IPP measurements.</p><p><strong>Conclusions: </strong>The presence of IPP exhibited an inverse relationship with SCC, suggesting diminished urine flow pressure over the prostatic urethra may reduce the likelihood of SCC formation. However, no direct association between PUA and the presence or severity of SCC was identified. These findings highlight the complexity of factors contributing to prostatic calculi development and the potential role of IPP in this context.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scoring system to evaluate meaningful fecal impaction in patients with lower urinary tract dysfunction with simple radiography (KUB). 通过简单射线照相术(KUB)评估下尿路功能障碍患者有意义的粪便嵌塞的评分系统。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-07-01 DOI: 10.4111/icu.20240086
Young Jae Im, Kyeong Chae Lee, Su Been Lee, Kyeong Kim, Kwanjin Park

Purpose: The management of bowel bladder disorder (BBD) has only been indicated for subjective constipation without objective evidence. We attempted to highlight the radiological findings in patients with BBD and construct a scoring system to identify patients with BBD prior to treatment.

Materials and methods: Forty-five patients with lower urinary tract dysfunction (LUTD) received polyethylene glycol for 2 months before bladder medication for LUTD. Based on partial response to LUTD following treatment, we divided the patients into LUTD-fecal impaction (FI) and LUTD not attributed to FI (LUTD-NFI) groups. Pre/post-treatment kidney, ureter, and bladder (KUB) were compared with respect to several radiographic parameters. Items with significant changes after treatment were included in the scoring system. The accuracy and inter-rater agreement were also evaluated.

Results: Cecal dilation, descending colon dilation, fecal quality, and overall haziness were found to undergo significant changes after laxative treatment. We assigned 0 to 2 points for each item, with a total score of 8. Receiver operating characteristic curve analysis revealed a cutoff value of 5 between LUTD-FI and LUTD-NFI, with 79% sensitivity and 88% specificity. The scoring system was instructed to six doctors who were unaware of it and was then tested on previous patients, which showed a substantial concordance rate (κ=0.79, p<0.05).

Conclusions: Fecal scoring system based on KUB was beneficial in identifying children with LUTD attributed to FI. This may provide an opportunity to obtain objective FI data as an alternative to subjective assessment of constipation.

目的:肠膀胱疾病(BBD)的治疗仅适用于无客观证据的主观便秘。我们试图强调 BBD 患者的放射学检查结果,并构建一个评分系统,以便在治疗前识别 BBD 患者:45名下尿路功能障碍(LUTD)患者在膀胱药物治疗LUTD前接受了2个月的聚乙二醇治疗。根据治疗后 LUTD 的部分反应,我们将患者分为 LUTD-粪便嵌塞(FI)组和 LUTD 非 FI 组(LUTD-NFI)。比较了治疗前/后肾脏、输尿管和膀胱(KUB)的多项放射学参数。治疗后有明显变化的项目被纳入评分系统。同时还评估了评分的准确性和评分者之间的一致性:结果:盲肠扩张、降结肠扩张、粪便质量和整体混浊度在通便治疗后发生了显著变化。接收者操作特征曲线分析显示,LUTD-FI 和 LUTD-NFI 的临界值为 5,灵敏度为 79%,特异度为 88%。向六位不了解该评分系统的医生介绍了该评分系统,然后在之前的患者身上进行了测试,结果显示两者的吻合率非常高(κ=0.79,pConclusions:基于 KUB 的粪便评分系统有助于识别因 FI 导致的 LUTD 儿童。这为获得客观的 FI 数据提供了机会,可替代对便秘的主观评估。
{"title":"Scoring system to evaluate meaningful fecal impaction in patients with lower urinary tract dysfunction with simple radiography (KUB).","authors":"Young Jae Im, Kyeong Chae Lee, Su Been Lee, Kyeong Kim, Kwanjin Park","doi":"10.4111/icu.20240086","DOIUrl":"10.4111/icu.20240086","url":null,"abstract":"<p><strong>Purpose: </strong>The management of bowel bladder disorder (BBD) has only been indicated for subjective constipation without objective evidence. We attempted to highlight the radiological findings in patients with BBD and construct a scoring system to identify patients with BBD prior to treatment.</p><p><strong>Materials and methods: </strong>Forty-five patients with lower urinary tract dysfunction (LUTD) received polyethylene glycol for 2 months before bladder medication for LUTD. Based on partial response to LUTD following treatment, we divided the patients into LUTD-fecal impaction (FI) and LUTD not attributed to FI (LUTD-NFI) groups. Pre/post-treatment kidney, ureter, and bladder (KUB) were compared with respect to several radiographic parameters. Items with significant changes after treatment were included in the scoring system. The accuracy and inter-rater agreement were also evaluated.</p><p><strong>Results: </strong>Cecal dilation, descending colon dilation, fecal quality, and overall haziness were found to undergo significant changes after laxative treatment. We assigned 0 to 2 points for each item, with a total score of 8. Receiver operating characteristic curve analysis revealed a cutoff value of 5 between LUTD-FI and LUTD-NFI, with 79% sensitivity and 88% specificity. The scoring system was instructed to six doctors who were unaware of it and was then tested on previous patients, which showed a substantial concordance rate (κ=0.79, p<0.05).</p><p><strong>Conclusions: </strong>Fecal scoring system based on KUB was beneficial in identifying children with LUTD attributed to FI. This may provide an opportunity to obtain objective FI data as an alternative to subjective assessment of constipation.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231666/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimated prospects of demand and supply of urologists in Korea over the next 10 years. 未来 10 年韩国泌尿科医生的供需前景预测。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-07-01 DOI: 10.4111/icu.20240101
Young Jae Im, Kwanjin Park, Youngho Oh, Jun Hyuk Hong, Sang Don Lee

Purpose: This study aimed to provide the basic data needed to estimate future urologist supply and demand by applying various statistical models related to healthcare utilization.

Materials and methods: Data from multiple sources, including the Yearbook of Health and Welfare Statistics, Korean Hospital Association, Korean Medical Association, and the Korean Urological Association, were used for supply estimation. Demand estimation incorporated data on both clinical and non-clinical urologists, along with future population estimates. In-and-out moves and demographic methods were employed for supply estimation, while the Bureau of Health Professions model was utilized for demand estimation. Supply estimation assumptions included fixed resident quotas, age-specific death rates, migration rates, and retirement age considerations. Demand estimation assumptions included combining clinical and nonclinical urologist demands, adjusting population size for age-related healthcare usage variations. Urologist productivity was determined by adjusting productivity levels to 100%, 90%, and 80% of the base year based on actual clinical practice volumes.

Results: Estimations of both demand and supply consistently indicate an oversupply of urologists until 2025, followed by an expected shortage by 2035 owing to increased deaths and retirements attributed to the aging urologist population. This shortage becomes more pronounced when employing more reliable models, such as logit or ARIMA (autoregressive integrated moving average), underscoring the growing need for urologists in the future.

Conclusions: All estimation models estimated an oversupply of urologists until 2025, transitioning to a deficit due to reduced supply thereafter. However, considering potential unaccounted factors, greater effort is needed for accurate predictions and corresponding measures.

目的:本研究旨在通过应用与医疗保健利用相关的各种统计模型,提供估算未来泌尿科医生供需情况所需的基本数据:供应估算使用了多种来源的数据,包括《保健福祉统计年鉴》、韩国医院协会、韩国医学协会和韩国泌尿外科协会。需求估算包括临床和非临床泌尿科医生的数据以及未来人口估算。供应估算采用了进出移动和人口统计方法,而需求估算则采用了卫生职业局模型。供应估算假设包括固定居民配额、特定年龄死亡率、迁移率和退休年龄因素。需求估算假设包括结合临床和非临床泌尿科医生需求,根据与年龄相关的医疗保健使用变化调整人口规模。泌尿科医生的生产力水平是根据实际临床实践量调整为基准年的 100%、90% 和 80%:结果:对需求和供应的估计一致表明,到 2025 年,泌尿科医生将供过于求,随后由于泌尿科医生人口老龄化导致死亡和退休人数增加,预计到 2035 年将出现短缺。如果采用更可靠的模型,如 logit 或 ARIMA(自回归综合移动平均值),这种短缺现象会更加明显,这突出表明未来对泌尿科医生的需求会越来越大:所有估计模型都估计 2025 年前泌尿科医生供过于求,之后由于供应减少而转为供不应求。然而,考虑到潜在的未考虑因素,要想做出准确的预测并采取相应的措施,还需要付出更大的努力。
{"title":"Estimated prospects of demand and supply of urologists in Korea over the next 10 years.","authors":"Young Jae Im, Kwanjin Park, Youngho Oh, Jun Hyuk Hong, Sang Don Lee","doi":"10.4111/icu.20240101","DOIUrl":"10.4111/icu.20240101","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to provide the basic data needed to estimate future urologist supply and demand by applying various statistical models related to healthcare utilization.</p><p><strong>Materials and methods: </strong>Data from multiple sources, including the Yearbook of Health and Welfare Statistics, Korean Hospital Association, Korean Medical Association, and the Korean Urological Association, were used for supply estimation. Demand estimation incorporated data on both clinical and non-clinical urologists, along with future population estimates. In-and-out moves and demographic methods were employed for supply estimation, while the Bureau of Health Professions model was utilized for demand estimation. Supply estimation assumptions included fixed resident quotas, age-specific death rates, migration rates, and retirement age considerations. Demand estimation assumptions included combining clinical and nonclinical urologist demands, adjusting population size for age-related healthcare usage variations. Urologist productivity was determined by adjusting productivity levels to 100%, 90%, and 80% of the base year based on actual clinical practice volumes.</p><p><strong>Results: </strong>Estimations of both demand and supply consistently indicate an oversupply of urologists until 2025, followed by an expected shortage by 2035 owing to increased deaths and retirements attributed to the aging urologist population. This shortage becomes more pronounced when employing more reliable models, such as logit or ARIMA (autoregressive integrated moving average), underscoring the growing need for urologists in the future.</p><p><strong>Conclusions: </strong>All estimation models estimated an oversupply of urologists until 2025, transitioning to a deficit due to reduced supply thereafter. However, considering potential unaccounted factors, greater effort is needed for accurate predictions and corresponding measures.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of the gender gap in urology industry payments: An Open Payments Program data analysis. 泌尿外科行业支付中的性别差距评估:开放支付计划数据分析。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-07-01 DOI: 10.4111/icu.20240021
Yuzhi Wang, Matthew James Davis, Alexandra Rogers, Jonathan Rexroth, Taylor Jane Malchow, Alex Stephens, Mohit Butaney, Samantha Wilder, Samantha Raffee, Firas Abdollah

Purpose: The Open Payments Program (OPP), established in 2013 under the Sunshine Act, mandated medical device and pharmaceutical manufacturers to submit records of financial incentives given to physicians for public availability. The study aims to characterize the gap in real general and real research payments between man and woman urologists.

Materials and methods: The study sample included all urologists in the United States who received at least one general or research payment in the OPP database from 2015 to 2021. Recipients were identified using the National Provider Identifier and National Downloadable File datasets. Payments were analyzed by geography, year, payment type, and years since graduation. Multivariable analysis on odds of being in above the median in terms of money received was done with gender as a covariate. This analysis was also completed for all academic urologists.

Results: There was a total of 15,980 urologists; 13.6% were woman, and 86.4% were man. Compared to man urologists, woman urologists were less likely to be in the top half of total payments received (odds ratio [OR] 0.62) when adjusted for other variables. When looking at academic urologists, 18.1% were woman and 81.9% were man. However, woman academic urologists were even less likely to be in the top 50% of payments received (OR 0.55).

Conclusions: This study is the first to characterize the difference in industry payments between man and woman urologists. The results should be utilized to educate physicians and industry, in order to achieve equitable engagement and funding for woman urologists.

目的:根据《阳光法案》(Sunshine Act)于 2013 年制定的 "公开付款计划"(OPP)规定,医疗设备和药品制造商必须提交给予医生的经济奖励记录,供公众查阅。本研究旨在描述男性和女性泌尿科医生在实际普通和实际研究费用方面的差距:研究样本包括美国所有泌尿科医生,他们在 2015 年至 2021 年期间至少在 OPP 数据库中获得过一次普通或研究付款。收款人通过国家提供者识别码和国家可下载文件数据集进行识别。支付情况按地域、年份、支付类型和毕业年限进行分析。在将性别作为协变量的情况下,对所获资金高于中位数的几率进行了多变量分析。这项分析也针对所有泌尿科医生进行:共有 15,980 名泌尿科医生,其中女性占 13.6%,男性占 86.4%。与男性泌尿科医生相比,在对其他变量进行调整后,女性泌尿科医生在总收入中排名前半部分的可能性较低(几率比 [OR] 0.62)。在学术型泌尿科医生中,女性占 18.1%,男性占 81.9%。然而,女性泌尿外科学术专家更不可能在所收薪酬中排名前 50%(OR 0.55):这项研究首次描述了男性和女性泌尿科医生在行业薪酬方面的差异。应利用研究结果对医生和业界进行教育,以实现女性泌尿科医生的公平参与和资助。
{"title":"Assessment of the gender gap in urology industry payments: An Open Payments Program data analysis.","authors":"Yuzhi Wang, Matthew James Davis, Alexandra Rogers, Jonathan Rexroth, Taylor Jane Malchow, Alex Stephens, Mohit Butaney, Samantha Wilder, Samantha Raffee, Firas Abdollah","doi":"10.4111/icu.20240021","DOIUrl":"10.4111/icu.20240021","url":null,"abstract":"<p><strong>Purpose: </strong>The Open Payments Program (OPP), established in 2013 under the Sunshine Act, mandated medical device and pharmaceutical manufacturers to submit records of financial incentives given to physicians for public availability. The study aims to characterize the gap in real general and real research payments between man and woman urologists.</p><p><strong>Materials and methods: </strong>The study sample included all urologists in the United States who received at least one general or research payment in the OPP database from 2015 to 2021. Recipients were identified using the National Provider Identifier and National Downloadable File datasets. Payments were analyzed by geography, year, payment type, and years since graduation. Multivariable analysis on odds of being in above the median in terms of money received was done with gender as a covariate. This analysis was also completed for all academic urologists.</p><p><strong>Results: </strong>There was a total of 15,980 urologists; 13.6% were woman, and 86.4% were man. Compared to man urologists, woman urologists were less likely to be in the top half of total payments received (odds ratio [OR] 0.62) when adjusted for other variables. When looking at academic urologists, 18.1% were woman and 81.9% were man. However, woman academic urologists were even less likely to be in the top 50% of payments received (OR 0.55).</p><p><strong>Conclusions: </strong>This study is the first to characterize the difference in industry payments between man and woman urologists. The results should be utilized to educate physicians and industry, in order to achieve equitable engagement and funding for woman urologists.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Computerized metric assessment of glandular tissue volume within the peripheral zone of the prostate using combined magnetic resonance imaging and histopathology: Possible pathophysiological implications on prostate cancer development. 利用磁共振成像和组织病理学对前列腺外周区腺体组织体积进行计算机计量评估:对前列腺癌发展的可能病理生理学影响。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-07-01 DOI: 10.4111/icu.20240040
John M Wolpert, Caroline Presson, Nathaniel Kimball, Benjamin Lin, Luis Brandi, Naseem Helo, Werner T W de Riese

Purpose: Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are prevalent urological ailments in elderly males. Numerous clinical studies have revealed an invert association between BPH/prostate size and PCa growth. This study investigates the association between prostate size and total glandular tissue volume of the peripheral zone (GVPZ) using a unique blend of magnetic resonance imaging (MRI) and histo-anatomical imaging technique.

Materials and methods: Patients were selected who underwent both radical prostatectomy and preoperative MRI scans. MRI scans provided quantitative measurements of prostatic zone dimensions, while histo-anatomical slides yielded quantitative data on glandular density of the peripheral zone (PZ) using imaging software. Integration of MRI and histopathology enabled the assessment of the GVPZ. Statistical analysis identified relationships between total prostate volume (TPV) and GVPZ.

Results: Seventy-two patients were selected and 40 cc was determined to be the optimal cutoff for small-to-moderate versus large prostates. Once the two subgroups in TPV were formed, the relationship between TPV and GVPZ was found to be highly significant (p<0.001).

Conclusions: The combination of MRI and histopathology offers a novel approach for precise quantification of glandular tissue within the prostatic PZ. This study corroborates the hypothesis of PZ compression via an enlarging transition zone in larger BPH prostates, resulting in PZ glandular atrophy. Given that most PCa originates in the PZ, these results shed light on the potential protective role of larger BPH prostates against PCa growth.

目的:良性前列腺增生症(BPH)和前列腺癌(PCa)是老年男性常见的泌尿系统疾病。大量临床研究表明,良性前列腺增生/前列腺大小与 PCa 生长之间存在反向关联。本研究采用独特的磁共振成像(MRI)和组织解剖成像技术,研究前列腺大小与外周区腺体组织总量(GVPZ)之间的关系:选取接受根治性前列腺切除术和术前磁共振成像扫描的患者。核磁共振成像扫描提供了前列腺区域尺寸的定量测量数据,而组织解剖切片则利用成像软件提供了外周区(PZ)腺体密度的定量数据。核磁共振成像与组织病理学的结合使我们能够评估前列腺外周区(GVPZ)。统计分析确定了前列腺总体积(TPV)和GVPZ之间的关系:结果:72 名患者被选中,40 毫升被确定为中小型前列腺与大型前列腺的最佳分界线。一旦 TPV 的两个亚组形成,TPV 和 GVPZ 之间的关系被发现具有高度显著性(pConclusions:核磁共振成像与组织病理学的结合为前列腺PZ内腺体组织的精确量化提供了一种新方法。这项研究证实了在较大的良性前列腺增生症前列腺中,PZ 通过扩大的过渡区受到挤压,从而导致 PZ 腺体萎缩的假说。鉴于大多数 PCa 都起源于 PZ,这些结果揭示了较大的良性前列腺增生症前列腺对 PCa 生长的潜在保护作用。
{"title":"Computerized metric assessment of glandular tissue volume within the peripheral zone of the prostate using combined magnetic resonance imaging and histopathology: Possible pathophysiological implications on prostate cancer development.","authors":"John M Wolpert, Caroline Presson, Nathaniel Kimball, Benjamin Lin, Luis Brandi, Naseem Helo, Werner T W de Riese","doi":"10.4111/icu.20240040","DOIUrl":"10.4111/icu.20240040","url":null,"abstract":"<p><strong>Purpose: </strong>Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are prevalent urological ailments in elderly males. Numerous clinical studies have revealed an invert association between BPH/prostate size and PCa growth. This study investigates the association between prostate size and total glandular tissue volume of the peripheral zone (GVPZ) using a unique blend of magnetic resonance imaging (MRI) and histo-anatomical imaging technique.</p><p><strong>Materials and methods: </strong>Patients were selected who underwent both radical prostatectomy and preoperative MRI scans. MRI scans provided quantitative measurements of prostatic zone dimensions, while histo-anatomical slides yielded quantitative data on glandular density of the peripheral zone (PZ) using imaging software. Integration of MRI and histopathology enabled the assessment of the GVPZ. Statistical analysis identified relationships between total prostate volume (TPV) and GVPZ.</p><p><strong>Results: </strong>Seventy-two patients were selected and 40 cc was determined to be the optimal cutoff for small-to-moderate versus large prostates. Once the two subgroups in TPV were formed, the relationship between TPV and GVPZ was found to be highly significant (p<0.001).</p><p><strong>Conclusions: </strong>The combination of MRI and histopathology offers a novel approach for precise quantification of glandular tissue within the prostatic PZ. This study corroborates the hypothesis of PZ compression via an enlarging transition zone in larger BPH prostates, resulting in PZ glandular atrophy. Given that most PCa originates in the PZ, these results shed light on the potential protective role of larger BPH prostates against PCa growth.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of family history of prostate cancer on disease progression for prostatic cancer patients undergoing active surveillance: A systematic review and meta-analysis. 前列腺癌家族史对接受主动监测的前列腺癌患者病情进展的影响:系统回顾和荟萃分析。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-07-01 DOI: 10.4111/icu.20240053
Jinhyung Jeon, Jae Heon Kim, Jee Soo Ha, Won Jae Yang, Kang Su Cho, Do Kyung Kim

Purpose: To evaluate how a family history of prostate cancer influences the progression of the disease in individuals with prostate cancer undergoing active surveillance.

Materials and methods: We conducted a thorough literature search in PubMed/MEDLINE, Embase, and Cochrane Library up to June 2023. This systematic review was registered in PROSPERO (CRD42023441853). The study evaluated the effects of family history of prostate cancer (intervention) on disease progression (outcome) in prostate cancer patients undergoing active surveillance (population) and compared them to those without a family history (comparators). For time to disease progression outcomes, the extracted data were synthesized using the inverse variance method on the log hazard ratios scale.

Results: A total of eight studies were incorporated into this systematic review and meta-analysis. The combined hazard ratio for unadjusted disease progression was 1.06 (95% confidential interval [CI] 0.66-1.69; p=0.82). The combined hazard ratio for adjusted disease progression was 1.31 (95% CI 1.16-1.48; p<0.0001). All the enlisted studies demonstrated high quality based on the Newcastle-Ottawa scale. The certainty of evidence for univariate and multivariate analysis of disease progression was very low and low, respectively. Publication bias for all studies was not significant.

Conclusions: For individuals with prostate cancer opting for active surveillance, a family history of prostate cancer may serve as an independent risk factor associated with an elevated risk of disease progression. Clinicians should be counseled about the increased risk of disease progression in patients with a family history of prostate cancer undergoing active surveillance.

目的:评估前列腺癌家族史如何影响接受主动监测的前列腺癌患者的病情进展:截至 2023 年 6 月,我们在 PubMed/MEDLINE、Embase 和 Cochrane 图书馆进行了全面的文献检索。本系统综述已在 PROSPERO(CRD42023441853)上注册。该研究评估了前列腺癌家族史(干预)对接受主动监测的前列腺癌患者(研究对象)疾病进展(结果)的影响,并与无家族史的患者(比较者)进行了比较。对于疾病进展时间结果,采用对数危险比的逆方差法对提取的数据进行了综合分析:本系统综述和荟萃分析共纳入了八项研究。未经调整的疾病进展综合危险比为 1.06(95% 置信区间 [CI] 0.66-1.69;P=0.82)。调整后疾病进展的综合危险比为1.31(95% CI 1.16-1.48;p结论:对于选择主动监测的前列腺癌患者来说,前列腺癌家族史可能是导致疾病进展风险升高的一个独立风险因素。临床医生应了解有前列腺癌家族史的患者接受主动监测后疾病进展的风险会增加。
{"title":"Impact of family history of prostate cancer on disease progression for prostatic cancer patients undergoing active surveillance: A systematic review and meta-analysis.","authors":"Jinhyung Jeon, Jae Heon Kim, Jee Soo Ha, Won Jae Yang, Kang Su Cho, Do Kyung Kim","doi":"10.4111/icu.20240053","DOIUrl":"10.4111/icu.20240053","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate how a family history of prostate cancer influences the progression of the disease in individuals with prostate cancer undergoing active surveillance.</p><p><strong>Materials and methods: </strong>We conducted a thorough literature search in PubMed/MEDLINE, Embase, and Cochrane Library up to June 2023. This systematic review was registered in PROSPERO (CRD42023441853). The study evaluated the effects of family history of prostate cancer (intervention) on disease progression (outcome) in prostate cancer patients undergoing active surveillance (population) and compared them to those without a family history (comparators). For time to disease progression outcomes, the extracted data were synthesized using the inverse variance method on the log hazard ratios scale.</p><p><strong>Results: </strong>A total of eight studies were incorporated into this systematic review and meta-analysis. The combined hazard ratio for unadjusted disease progression was 1.06 (95% confidential interval [CI] 0.66-1.69; p=0.82). The combined hazard ratio for adjusted disease progression was 1.31 (95% CI 1.16-1.48; p<0.0001). All the enlisted studies demonstrated high quality based on the Newcastle-Ottawa scale. The certainty of evidence for univariate and multivariate analysis of disease progression was very low and low, respectively. Publication bias for all studies was not significant.</p><p><strong>Conclusions: </strong>For individuals with prostate cancer opting for active surveillance, a family history of prostate cancer may serve as an independent risk factor associated with an elevated risk of disease progression. Clinicians should be counseled about the increased risk of disease progression in patients with a family history of prostate cancer undergoing active surveillance.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical outcomes of holmium laser enucleation of the prostate: A large prospective registry-based patient cohort study under regular follow-up protocol. 前列腺钬激光去核术的临床效果:定期随访的大型前瞻性登记患者队列研究。
IF 2.5 3区 医学 Q2 UROLOGY & NEPHROLOGY Pub Date : 2024-07-01 DOI: 10.4111/icu.20240080
Hyomyoung Lee, Sangwon So, Min Chul Cho, Sung Yong Cho, Jae-Seung Paick, Seung-June Oh

Purpose: To evaluate the efficacy and safety of holmium laser enucleation of the prostate (HoLEP) in a large prospective cohort of patients with benign prostatic hyperplasia (BPH) through systematic follow-up at a single institution.

Materials and methods: Clinical outcomes were analyzed between August 2008 and June 2022. Patients were followed-up at 2 weeks, 3 months and 6 months postoperatively.

Results: A total of 3,000 patients (mean age, 69.6±7.7 years) underwent HoLEP. Baseline total International Prostate Symptom Score (IPSS) was 19.3±7.7 and maximum flow rate (Qmax) was 9.4±4.8 mL/s. Mean total prostate volume was 67.7±3.4 mL. Total operation time was 60.7±31.5 minutes, and catheterization time was 1.0 days (range, 1.0-1.0 days). At 6 months postoperatively, the total IPSS decreased to 6.6±5.8 and Qmax increased to 22.2±11.3 mL/s. Complications at 6 months postoperatively included stress urinary incontinence (SUI) in 36 patients (1.9%), urgency urinary incontinence (UUI) in 25 (1.3%), bladder neck contracture (BNC) requiring transurethral incision (TUI) in 16 (0.5%), and urethral stricture in 29 (1.0%). Eleven patients (0.4%) with prostatic fossa stones required stone removal. Sixty-one patients (2.0%) required secondary surgery (transurethral coagulation, 16 [0.5%]; TUI for BNC, 16 [0.5%]; stone removal for prostatic fossa stones, 11 [0.4%]; and endoscopic internal urethrotomy for urethral stricture, 18 [0.6%]).

Conclusions: Mid-term follow-up results after HoLEP in BPH patients showed excellent efficacy and low complication rates. Unlike previous reports, the incidence of SUI and UUI after HoLEP was low, but the occurrence of de novo stone formation in prostatic fossa was notable.

目的:通过在一家机构进行系统随访,评估前列腺钬激光去核术(HoLEP)在大量前瞻性良性前列腺增生症(BPH)患者中的疗效和安全性:对2008年8月至2022年6月期间的临床结果进行了分析。对患者进行了术后2周、3个月和6个月的随访:结果:共有3000名患者(平均年龄为69.6±7.7岁)接受了HoLEP手术。基线国际前列腺症状总评分(IPSS)为(19.3±7.7)分,最大流速(Qmax)为(9.4±4.8)毫升/秒。前列腺平均总体积为 67.7±3.4 mL。手术总时间为 60.7±31.5 分钟,导管插入时间为 1.0 天(范围为 1.0-1.0 天)。术后6个月,总IPSS降至6.6±5.8,Qmax增至22.2±11.3 mL/s。术后6个月的并发症包括:36名患者(1.9%)出现压力性尿失禁(SUI),25名患者(1.3%)出现急迫性尿失禁(UUI),16名患者(0.5%)出现膀胱颈挛缩(BNC),需要经尿道切开术(TUI),29名患者(1.0%)出现尿道狭窄。11名前列腺窝结石患者(0.4%)需要进行结石清除术。61名患者(2.0%)需要进行二次手术(经尿道电凝,16人[0.5%];TUI治疗BNC,16人[0.5%];前列腺窝结石取石,11人[0.4%];内镜下尿道内切开术治疗尿道狭窄,18人[0.6%]):结论:对良性前列腺增生患者进行HoLEP术后的中期随访结果显示,疗效极佳,并发症发生率较低。与之前的报告不同,HoLEP术后SUI和UUI的发生率很低,但前列腺窝内新结石的形成却很显著。
{"title":"Clinical outcomes of holmium laser enucleation of the prostate: A large prospective registry-based patient cohort study under regular follow-up protocol.","authors":"Hyomyoung Lee, Sangwon So, Min Chul Cho, Sung Yong Cho, Jae-Seung Paick, Seung-June Oh","doi":"10.4111/icu.20240080","DOIUrl":"10.4111/icu.20240080","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the efficacy and safety of holmium laser enucleation of the prostate (HoLEP) in a large prospective cohort of patients with benign prostatic hyperplasia (BPH) through systematic follow-up at a single institution.</p><p><strong>Materials and methods: </strong>Clinical outcomes were analyzed between August 2008 and June 2022. Patients were followed-up at 2 weeks, 3 months and 6 months postoperatively.</p><p><strong>Results: </strong>A total of 3,000 patients (mean age, 69.6±7.7 years) underwent HoLEP. Baseline total International Prostate Symptom Score (IPSS) was 19.3±7.7 and maximum flow rate (Qmax) was 9.4±4.8 mL/s. Mean total prostate volume was 67.7±3.4 mL. Total operation time was 60.7±31.5 minutes, and catheterization time was 1.0 days (range, 1.0-1.0 days). At 6 months postoperatively, the total IPSS decreased to 6.6±5.8 and Qmax increased to 22.2±11.3 mL/s. Complications at 6 months postoperatively included stress urinary incontinence (SUI) in 36 patients (1.9%), urgency urinary incontinence (UUI) in 25 (1.3%), bladder neck contracture (BNC) requiring transurethral incision (TUI) in 16 (0.5%), and urethral stricture in 29 (1.0%). Eleven patients (0.4%) with prostatic fossa stones required stone removal. Sixty-one patients (2.0%) required secondary surgery (transurethral coagulation, 16 [0.5%]; TUI for BNC, 16 [0.5%]; stone removal for prostatic fossa stones, 11 [0.4%]; and endoscopic internal urethrotomy for urethral stricture, 18 [0.6%]).</p><p><strong>Conclusions: </strong>Mid-term follow-up results after HoLEP in BPH patients showed excellent efficacy and low complication rates. Unlike previous reports, the incidence of SUI and UUI after HoLEP was low, but the occurrence of <i>de novo</i> stone formation in prostatic fossa was notable.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Investigative and Clinical Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1